Myovant and Pfizer’s uterine fibroids med scores FDA nod, setting up showdown with AbbVie
Fresh off the back of Myovant Sciences’ first FDA win for relugolix in prostate cancer late last year, the Swiss pharma can now add a second indication to its flagship drug’s resume. The U.S. FDA on Wednesday approved Myovant’s relugolix in combination with two hormone drugs as the first once-daily treatment for heavy menstrual bleeding linked to… Read More »